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Abstract
There are currently five invasive Aedes mosquito species known to be established in Europe, namely Aedes albopictus, Aedes aegypti, Aedes
japonicus, Aedes atropalpus and Aedes koreicus. Aedes albopictus and Aedes aegypti are the incriminated vectors in the recent outbreaks of
chikungunya and dengue fever in Europe. However, both laboratory experiments and field observations indicate that these invasive
mosquitoes have a potential to also transmit other pathogens of public health importance. Increasing travel and pathogen introduction,
expansion of vector distribution, and both environmental and climatic changes are likely to raise the risk of pathogen transmission by these
invasive Aedes mosquitoes. Their vector status and their involvement in pathogen transmission are dynamic processes that shape the future
of mosquito-borne disease epidemiology in Europe. Beside vector surveillance, enhanced disease surveillance will enable the early detection
of cases and the prompt implementation of control measures.
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Invasive Mosquito Species in Europe
Invasive mosquito species are defined by their ability to
colonise new territories and to cause or to be likely to cause
harm to the economy, environment, or human health. Human
actions are the primary means of introduction of invasive
species. A considerable increase in the spread of invasive
mosquitoes has been observed within Europe since the late
1990s, with the Asian tiger mosquito Aedes albopictus (Fig. 1)
having continuously expanded its distribution, and several
other container-breeding Aedes species now being reported
from new countries every year (details about successive
introductions and spread in Europe are given in [1]). To date,
Ae. albopictus has colonised almost all Mediterranean coun-
tries, whereas the Asian bush mosquito Aedes japonicus (Fig. 2)
is spreading widely in Central Europe. Two other species,
Aedes atropalpus and Aedes koreicus, have been introduced on
several occasions, leading to the establishment of populations
at few foci. Aedes triseriatus was intercepted at a point of entry,
and its establishment was prevented by the implementation of
immediate control measures. Finally, the yellow fever mos-
quito Aedes aegypti (Fig. 3), which had been introduced into
Europe during the 17–19th centuries, existed in southern
Europe until its disappearance during the 20th century. This
species has now returned, having recently established on
Madeira as well as around the Black Sea coast (Russia,
Abkhazia, Georgia). These invasive mosquito species are well
adapted to synanthropic settings where they exploit the
abundant sources of host blood, resting places and larval
breeding sites (mainly man-made water containers) [2].
Mosquito-Borne Pathogens Transmitted by
Invasive Mosquitoes in Europe
Although mosquito-borne diseases (MBDs) represent a lower
burden in temperate compared to tropical regions where they
pose a substantial impact on the countries’ socio-economic
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development, there have always been both endemic and
epidemic autochthonous MBDs in Europe. Concern is now
rising as both vectors and pathogens are increasingly being
introduced by international travel and trade. Some of these
diseases are emerging or are reappearing after a long period of
absence. Their occurrence is often associated with changes in
ecosystems, human behaviour, and climate [3].
The first notable outbreak of a MBD attributed to invasive
mosquitoes in Europe occurred in 2007 in Ravenna, Italy,
where more than 200 confirmed chikungunya cases were
reported between July and September [4–7]. The index case
was most likely a traveller returning from the state of Kerala,
India, and the first local case was a relative that he visited [8].
Indeed, the strain that caused the outbreak in Italy was
genetically similar to the strains from the Indian subcontinent
and showed the mutation that is believed to be better adapted
to Ae. albopictus [6]. The rapid spread of the infection from one
index case demonstrated the efficiency of local Ae. albopictus
populations to transmit chikungunya virus (CHIKV). The second
autochthonous transmission of CHIKV in Europe occurred in
southern France (Frejus, department of Var) in 2010. The
presumed index case who had returned from Rajasthan, India,
sought medical care in late August and lived in the close vicinity
of one of the two local cases who developed symptoms in
September. The origin of the viral strain circulating in France
was confirmed to be from northern India [9].
In the same year, two cases of autochthonous dengue fever
occurred in Nice, France. This was the first local transmission
of dengue virus (DENV) in Europe, since the major dengue
epidemic of 1927–1928 in Greece where Ae. aegypti was
implicated as the vector [10]. The first patient developed
symptoms in late August 2010 and was detected through a
routine enhanced surveillance system coordinated by the
French authorities in the departments where Ae. albopictus had
become established. The second case lived near the first case
and developed symptoms by mid-September 2010 [11].
Subsequently, Croatia was the second country in Europe with
autochthonous transmission of DENV in 2010 [12]. The first
case was reported by the German health authorities that
notified a laboratory-confirmed case in a German citizen
returning from southern Croatia. The patient had spent
2 weeks on the Peljesac peninsula in early August [13].
A second case was reported in late October through active
case finding in the same village where the infected tourist had
stayed [12]. In addition, further evidence of indigenous
FIG. 1. Aedes albopictus, female. Source: F. Schaffner/Avia-GIS.
FIG. 2. Aedes japonicus, female. Source: F. Schaffner/Avia-GIS.
FIG. 3. Aedes aegypti, female. Source: F. Schaffner/Avia-GIS.
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transmission was suggested by positive laboratory results from
14 healthy individuals [12] and by a sero-prevalence survey
using a random sample of the population living in the area [14].
Currently, a large outbreak of dengue fever is on-going in the
Portuguese Autonomous Region of Madeira [15]. The epi-
demic started in October 2012 and by early January 2013
more than 2000 cases of dengue fever had been reported, with
an additional 70 cases reported among European travellers
returning from the island [16]. The presence of Ae. aegypti in
Madeira has been known since 2005 but this is the first
recorded outbreak of dengue on the island.
Since the 2007 outbreak of chikungunya in Italy, it is
acknowledged that Europe is vulnerable for transmission of
‘tropical’ arboviruses, particularly in regions where Ae. albo-
pictus or Ae. aegypti are present.
Potential Vector Role of Invasive Mosquitoes
Outside Europe, Ae. albopictus was implicated in transmission
of CHIKV causing large scale disease outbreaks in the Indian
Ocean and south Asia since 2005 [17]. Previously, Ae. albopic-
tus was responsible for DENV transmission in the 1977–78
Reunion Island epidemic, in an outbreak in Hawaii in 2001–
2002 [18] and again in Reunion Island (2004) [19], Gabon
(2007) [20], and Mauritius (2009) [21]. Aedes albopictus is also a
known vector of Dirofilaria filarial nematodes, which primarily
are parasites of dogs but can also affect humans. Recent
evidence of transmission by Italian Ae. albopictus populations
[22,23] has been linked to an increase in prevalence of human
dirofilariosis [24]. Other arboviruses important to human
health that have been isolated from field-collected Ae. albopic-
tus or for which laboratory transmission has been demon-
strated [25] include Eastern equine encephalitis (EEEV) [26,27],
Jamestown Canyon virus (JCV) [28], Japanese encephalitis virus
(JEV) [25], La Crosse virus (LACV) [29,30], Venezuelan equine
encephalitis virus (VEEV) [31,32], and West Nile virus (WNV)
[33,34]. Field isolations and experimental infection studies
alone, however, simply indicate the potential of a mosquito
species to transmit these viruses but cannot prove its
epidemiological role. Major dengue fever epidemics due to
Ae. aegypti occur in the Americas, South East Asia and the
western Pacific, and the disease is now endemic in >100
countries worldwide [35]. When this mosquito was wide-
spread in southern Europe, it was responsible for large
epidemics of dengue and yellow fever [10,36,37]. Aedes aegypti
has recently been implicated in outbreaks of chikungunya,
notably in Kenya and the Comoros Islands [38]. It is also a
highly effective vector of yellow fever virus (YFV) in Africa and
South America [39]. Historically, local outbreaks of yellow
fever were reported from several ports in Europe (France,
Great Britain, Italy, Portugal, Spain) in the 19th century
following importations of the vector and viraemic passengers
aboard vessels, with occasional large inland outbreaks where
Ae. aegypti was established (e.g. Barcelona, Lisbon) [37].
Imported yellow fever cases are occasionally noted across
Europe [40–42] with high case-fatality rates. In addition,
Ae. aegypti was suggested as a vector of Zika virus (ZIKV)
owing to virus isolation from field collections [43] and virus
transmission under laboratory conditions [44].
Regarding the other invasive species, laboratory compe-
tency studies have shown the ability of Ae. atropalpus to
transmit LACV [45], WNV [46] and other arboviruses causing
encephalitis, but its importance as a vector of human
pathogens is still not clear [47]. Field-collected Ae. japonicus
have been found positive for WNV on a number of occasions
in the US [48], and laboratory studies showed its high vector
competence for WNV [46,49] and also for DENV [50], JEV
[51], and LACV [52], whereas it was a moderately efficient
vector for CHIKV [50], EEEV [53] and Saint Louis encephalitis
virus (SLEV) [54]. However, its role in the transmission of
these viruses under natural conditions remains unclear [55]. In
North America, Ae. triseriatus is a known vector of LACV
causing serious disease in humans [56,57], and JCV has
repeatedly been isolated from field-collected specimens in
the US [58]. It is also suggested to be a possible bridge vector
for WNV, based on virus isolations from field collections [59]
and vector competence demonstrated under laboratory
conditions [60]. Other laboratory studies have shown vector
competence for VEEV [61], EEEV, Western equine encephalitis
virus (WEEV), DENV, SLEV and YFV [62]. Aedes koreicus has
been linked to outbreaks of JEV [63] and Dirofilaria [64] but is
not a confirmed vector of either pathogen.
Invasive Mosquitoes in Europe: A Growing
Threat to Public Health?
Pathogen transmission by arthropod vectors depends on
multiple factors which define their vectorial capacity C, i.e.
the daily rate of future inoculations originating from a
currently infective source. In the equation C = b m a2 pt/(ln
p) [65], where b is the vector competence, i.e. the
proportion of vectors that develop infective pathogen stages;
m the vector density in relation to host density; a the
vector’s daily blood-feeding rate; p the vector’s daily survival
rate; t the duration of the pathogen’s extrinsic incubation
period in days. The vector capacity is specific to a species
population in a defined natural context. The vector compe-
tence (b) refers to innate factors influencing the ability of a
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vector to transmit a pathogen. It is of primary importance,
and it can be assessed in the laboratory by experimental
infection, indicating the potential for involvement in trans-
mission (Table 1), which is specific to each mosquito species
and may vary between populations of a defined species
[66,67]. DNA mutation of an arboviral protein can alter the
transmission efficiency of a mosquito species, as observed in
Ae. albopictus for CHIKV where a single amino acid substi-
tution led to a reduction of the extrinsic incubation period
and to an increase in transmission efficiency [68,69]. Besides
being competent for a pathogen, a mosquito species needs to
both sustain pathogen development under natural tempera-
ture ranges (t) and have a sufficient daily survival rate (p) to
transmit the pathogen. Population density (m) and vector-
host contact rate (a) need to be high enough to sustain the
transmission cycle and, in cases where the pathogen has non-
human reservoir hosts, the mosquitoes must blood-feed on
both these animal hosts and humans.
TABLE 1. Main mosquito-borne pathogens that can be transmitted by invasive aedine mosquitoes
Pathogen Genus Clinical importance Disease occurrence
Role of invasive
species
(confirmeda/
laboratoryb)
Chikungunya virus
(CHIKV)
Alphavirus Chikungunya infection can cause fever, myalgia, rash and strong arthralgia
which often lasts for months in up to 65% of patients [88]; Clinical
manifestations observed during an epidemic on La Reunion included
severe hepatitis, severe maternal and foetal disease and
meningeoencephalitis [89]; There is currently no licensed vaccine
against CHIKV [90]
Endemic in Africa and Asia;
Frequently imported into
Europe
Ae. aegypti
Ae. albopictus
Ae. japonicus
Eastern equine
encephalitis virus
(EEEV)
Alphavirus Severe cases of EEEV infection involving encephalitis begin with the sudden
onset of headache, high fever, chills, and vomiting; The illness may then
progress into disorientation, seizures, or coma, with fatality rates
reaching up to 70% during some epidemics [91]
Americas; No evidence of
introduction into Europe
to date
Ae. albopictus
Ae. triseriatus
Venezuelan equine
encephalitis virus
(VEEV)
Alphavirus Largely subclinical, however can cause a nonspecific viral syndrome
and rarely neurological complications such as encephalitis, more
frequently in children than in adults, including death
(fatality rate of 1 to 3%) [91,92]
Endemic in the Americas; No
evidence of introduction into
Europe to date
Ae. albopictus
Ae. triseriatus
Western equine
encephalitis virus
(WEEV)
Alphavirus Symptoms range from mild flu-like illness to severe encephalitis, coma
and death, with a fatality rate up to 5%, and higher manifestation rates
in children and in elderly persons [91]
Endemic in western part of
North America; No evidence of
introduction into Europe to date
Ae. triseriatus
Jamestown Canyon
virus (JCV)
Bunyavirus Probably most cases are subclinical, and rare human clinical cases show
mild febrile illness and at some occasions acute central nervous system
infection including meningitis and encephalitis [58,93]
Endemic in North America;
No evidence of introduction
into Europe to date
Ae. albopictus
Ae. triseriatus
Dengue virus (DENV) Flavivirus Dengue consists of 4 viral serotypes; The infection causes a flu-like illness
which includes fever, intense headache, muscular and joint pain, anorexia,
nausea, vomiting and rashes; Sometimes it leads to life-threatening
complications including severe bleeding and shock [21,94]; Severe dengue
case fatality rates can reach 50% in untreated cases [78]; There is no
vaccine available but several candidates are under clinical trials [95]
Endemic in Africa, Americas and
Caribbean, Asia; Frequently
imported into Europe
Ae. aegypti
Ae. albopictus
Ae. japonicus
Ae. triseriatus
Japanese encephalitis
virus (JEV)
Flavivirus Most cases are subclinical or result in mild symptoms only; However,
a small percentage of cases develop encephalitis, with symptoms including
sudden onset of headache, high fever, disorientation, coma, tremors and
convulsions; It affects primarily children, fatality rate ranges from 10 to
35% and as many as 35% of survivors may have serious life-long
neurologic sequelae [92]; Currently the most important mosquito-
transmitted arbovirus causing encephalitis in the world, causing 30,000 to
50,000 human cases every year [91]; Vaccines are available
Endemic in Asia; No clear
evidence of introduction
into Europe to date
Ae. albopictus
Ae. japonicus
Ae. koreicus
St. Louis encephalitis
virus (SLEV)
Flavivirus Most cases are subclinical; Initial symptoms in clinically apparent cases
(less than 1%) include fever, headache, nausea, vomiting, and tiredness;
Severe neuroinvasive disease (often involving meningoencephalitis)
occurs more commonly in older adults; In rare cases, long-term disability
or death can result [96]
Endemic in the Americas;
No evidence of introduction
into Europe to date
Ae. japonicus
Ae. triseriatus
West Nile virus
(WNV)
Flavivirus 80% of WNV infection cases are subclinical, and 20% present mild
influenza-like illness (fever, headache, body ache); Less than 1% of the
cases develop more severe disease, such as encephalitis, meningitis
or meningo-encephalitis, mainly in the elderly with fatality rates
up to 20% [92]
Worldwide Ae. albopictus
Ae. atropalpus
Ae. japonicus
Ae. triseriatus
Yellow fever virus
(YFV)
Flavivirus YFV can cause systemic disease including fever, jaundice, haemorrhage and
renal failure; Approximately 200,000 cases are reported annually [97];
Symptoms are present in about 1 in 7 of those infected [42] and the
mortality rate is 20-50%; There is an effective live-attenuated virus
vaccine for YFV which can help to prevent the disease [92]
Endemic in Africa and
South America; Occasionally
imported into Europe
Ae. aegypti
Ae. triseriatus
Zika virus (ZIKV) Flavivirus ZIKV can cause headache, rash, malaise and back pain [98] Epidemic in Africa, Asia Ae. aegypti
La Crosse virus
(LACV)
Orthobunyavirus LACV can cause serious neuroinvasive disease in humans (fatality rate
of 0.3%); It is the common cause of paediatric arboviral encephalitis in the
US with 40 to 170 cases reported annually and 90% of those infected are
under the age of 15 [56]; Case numbers, however, are suspected to be
underestimated [57]; Prior to WNV spread it was considered one of the
most important mosquito-borne diseases in the US [45]; Most human
infections occur from July to September [56]
Endemic in northern America;
No evidence of introduction
into Europe to date
Ae. albopictus
Ae. atropalpus
Ae. japonicus
Ae. triseriatus
Dirofilaria immitis,
D. repens
Dirofilaria In most human infections, larvae are destroyed by the immune system
but in some cases, adult worms can develop, resulting in pulmonary
or subcutaneous infections [99]
Endemic in southern Europe
and the Americas
Ae. albopictus
Ae. koreicus
aConfirmed’ refers to evidence of the implication of a species (in bold characters) as vector for a defined pathogen on the field.
bLaboratory’ refers to demonstration of the ability of a species (in regular characters) to transmit a defined pathogen in laboratory experiments (vector competence).
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Introduced mosquitoes may affect human health by (i)
concurrently harbouring novel pathogens, (ii) transmitting
native pathogens, or (iii) transmitting novel pathogens that
were independently introduced [70]. The first scenario
occurred during the 18th and 19th centuries in Europe with
Ae. aegypti carrying YFV and DENV, causing disease outbreaks
in ports and other places [10,71]. In the second scenario, the
transmission rate of an indigenous pathogen may increase
because of a high vector capacity of the invasive vector, as
observed for Dirofilaria transmission in Italy in areas colonised
by Ae. albopictus [24]. The third scenario appears to be the
most common one for disease emergence, and it applies to the
recently observed transmission of DENV and CHIKV, with
various time periods elapsed between the introduction of the
vector and the first outbreak (e.g. first CHIKV transmission
occurred 17 years after the establishment of Ae. albopictus in
Italy but only after 4 years in southern France), depending
upon the global context (e.g. frequency and intensity of
epidemics in dengue-endemic areas). The first and third
scenarios have the potential to lead to large disease outbreaks,
in particular because of a limited immunity of individuals in a
population.
Considering the increasing frequency of both dengue and
chikungunya epidemics worldwide and the movement of
viraemic hosts, it is expected that new autochthonous cases
of dengue and/or chikungunya fever will occur in the future
[14]. It is estimated that 22.5 million travellers arrive in
Europe each year, and as many as 185 000 of these could be
viraemic for CHIKV [72]. Environmental changes such as land
cover change or changes in weather patterns are known to
impact vector-borne disease transmission [73]. Climate change
could facilitate higher mosquito densities of Ae. albopictus or its
establishment or spread beyond the current boundaries. It
may result in transient summer expansions, or new foci of
established populations, at locations where temperature and
humidity are more suitable, thus enhancing the transmission
potential for CHIKV and DENV in temperate regions [38,74–
76]. However, demographic- and anthropogenic-driven envi-
ronmental changes combined with globalisation and inefficient
public health measures are considered the principal driving
forces for the emergence and global spread of dengue in the
past 40 years [77]. Aedes albopictus mosquitoes have the
propensity to feed on multiple hosts and, therefore, contribute
to the risk of transmission of zoonotic disease agents, whereas
the strict anthropophily of Ae. aegypti favours transmission of
anthroponosis [25]. Indeed, Ae. albopictus is considered to play
a minor role compared to Ae. aegypti in DENV transmission,
due to differences in host preferences and to lower vector
competence [25,66]. In summary, the presence of Ae. aegypti
and Ae. albopictus in Europe and the increasing number of
overseas travellers may increase the risk of transmission of
DENV and CHIKV in Europe [78]. Aedes japonicus deserves
attention regarding its potential to transmit pathogens,
including DENV and CHIKV, owing to high population
densities in urban environments, its continuing spread in
central Europe, its vector competence for several viruses
under laboratory conditions, and its anthropophilic nature [F.
Schaffner unpublished data, 50,79–81]. The other invasive
species discussed here (Ae. atropalpus, Ae. koreicus, Ae. triseri-
atus) currently represent a very low risk for public health in
Europe, considering their limited distribution. Given the
recent developments, surveillance of all invasive aedine
mosquitoes is now essential to detect early the presence of
these mosquitoes, to assess the risk of MBDs and to prepare
for the control of disease outbreaks [2]. The elimination of the
species at an early stage of introduction, before it becomes
widely established, has been achieved at some foci (e.g. in
France [82], Italy [83], and The Netherlands [84,85]). When
the species is widely established, the purpose of the control is
usually limited to reducing the risk for disease transmission
and biting nuisance. A number of control methods are
commonly used such as source reduction, pesticide applica-
tion, biological control, and public education. These methods
are often combined as an integrated vector management
strategy which so far seems to give the best results [86,87].
However, the control of Ae. albopictus has so far proven
difficult with the currently available control methods and
alternative innovative techniques are needed [1] as well as
strategies to prevent the introduction of invasive Aedes
species. Co-ordination among countries will be essential
considering the cross-boundary aspects of the problem.
Furthermore, fundamental knowledge on the relevant breed-
ing places, host preferences and longevity of these invasive
mosquito species under European conditions as well as on
their vector competences for important viruses is required to
better target and control these species. Vector status is a
dynamic process that in the future could impact significantly on
MBD epidemiology. Beside vector surveillance, enhanced
disease surveillance will enable the early detection of cases
and the prompt implementation of control measures.
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